MX2018012945A - Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre. - Google Patents

Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.

Info

Publication number
MX2018012945A
MX2018012945A MX2018012945A MX2018012945A MX2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A
Authority
MX
Mexico
Prior art keywords
dendrithic
blood
cells
pharmaceutical compositions
clinical use
Prior art date
Application number
MX2018012945A
Other languages
English (en)
Spanish (es)
Inventor
Martin David
R H Krebs Mark
Dai David
Sule Shantanu
Rabah Dania
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2018012945A publication Critical patent/MX2018012945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2018012945A 2016-04-28 2017-04-27 Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre. MX2018012945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (1)

Publication Number Publication Date
MX2018012945A true MX2018012945A (es) 2019-03-06

Family

ID=58672794

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018012945A MX2018012945A (es) 2016-04-28 2017-04-27 Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.
MX2025000037A MX2025000037A (es) 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre
MX2023008075A MX2023008075A (es) 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2025000037A MX2025000037A (es) 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre
MX2023008075A MX2023008075A (es) 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.

Country Status (16)

Country Link
US (2) US20190284281A1 (cg-RX-API-DMAC7.html)
EP (1) EP3448425A1 (cg-RX-API-DMAC7.html)
JP (3) JP7045327B2 (cg-RX-API-DMAC7.html)
KR (5) KR20250088784A (cg-RX-API-DMAC7.html)
CN (2) CN109475623B (cg-RX-API-DMAC7.html)
AU (2) AU2017258191B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072125A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022116A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018012506A2 (cg-RX-API-DMAC7.html)
EA (1) EA201892443A1 (cg-RX-API-DMAC7.html)
IL (2) IL262514B2 (cg-RX-API-DMAC7.html)
MA (1) MA44763A (cg-RX-API-DMAC7.html)
MX (3) MX2018012945A (cg-RX-API-DMAC7.html)
NZ (2) NZ747504A (cg-RX-API-DMAC7.html)
PH (1) PH12018502278A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017189827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
PE20231678A1 (es) 2020-12-03 2023-10-19 Biogen Ma Inc Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico
CN118055781A (zh) 2021-08-09 2024-05-17 株式会社茵温特拉 注入到生物体内后以不被巨噬细胞吞噬和/或不被代谢分解的状态通过肾脏由尿液排出的纳米结构物
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
EP4643887A1 (en) * 2022-12-28 2025-11-05 Duality Biologics (Shanghai) Co., Ltd. Anti-bdca2 antibody-drug conjugate and use thereof
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
HUE047874T2 (hu) * 2012-12-10 2020-05-28 Biogen Ma Inc Vér dendritikus sejt antigén 2 elleni antitestek és alkalmazásuk

Also Published As

Publication number Publication date
WO2017189827A1 (en) 2017-11-02
EP3448425A1 (en) 2019-03-06
KR20240033168A (ko) 2024-03-12
IL321561A (en) 2025-08-01
AU2017258191B2 (en) 2024-06-13
EA201892443A1 (ru) 2019-04-30
KR20250088784A (ko) 2025-06-17
NZ747504A (en) 2025-08-29
JP2022084782A (ja) 2022-06-07
KR20190002563A (ko) 2019-01-08
IL262514A (en) 2018-12-31
CO2018012506A2 (es) 2018-12-14
MX2023008075A (es) 2023-07-18
JP2024038308A (ja) 2024-03-19
JP7045327B2 (ja) 2022-03-31
JP2019520316A (ja) 2019-07-18
IL262514B2 (en) 2025-12-01
KR102366547B1 (ko) 2022-02-23
NZ787392A (en) 2025-08-29
CN109475623A (zh) 2019-03-15
BR112018072125A2 (pt) 2019-03-19
KR20240159012A (ko) 2024-11-05
MA44763A (fr) 2019-03-06
AU2024203240A1 (en) 2024-06-13
US20190284281A1 (en) 2019-09-19
AU2017258191A1 (en) 2018-11-15
PH12018502278A1 (en) 2019-09-09
CA3022116A1 (en) 2017-11-02
MX2025000037A (es) 2025-02-10
US20250289895A1 (en) 2025-09-18
IL262514B1 (en) 2025-08-01
CN109475623B (zh) 2023-05-26
KR20220028150A (ko) 2022-03-08
CN116850282A (zh) 2023-10-10

Similar Documents

Publication Publication Date Title
MX2018012945A (es) Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.
MX2021001837A (es) Constructos del receptor de celulas t y usos de los mismos.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
AR113142A1 (es) Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
MA39096B1 (fr) Anticorps spécifiques à fcrn
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
CL2015002835A1 (es) Nuevos derivados de piridina
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
CO2020006855A2 (es) Composiciones y métodos para el agotamiento de células cd2+
PH12019500949A1 (en) Ror-gamma modulators
MX2024004652A (es) Pautas posologicas para la movilizacion de celulas madre y progenitoras hematopoyeticas.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
PH12018502139A1 (en) Phosphaplatin liquid formulations
EP3826626A4 (en) USE OF ANTI-CD137 ANTIBODY-DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY